Skip to main content

medimmune-logo

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and MedImmune, the global biologics research and development arm of AstraZeneca (LSE: AZN, SSE: AZN, NYSE: AZN), today announced that they have entered into a licensing agreement under which Regeneron will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody- drug conjugates (ADCs) as potential cancer treatments.

{iframe}https://www.twst.com/update/regeneron-pharmaceuticals-inc-regeneron-and-medimmune-enter-into-licensing-agreement-for-the-development-of-antibody-drug-conjugates-to-treat-cancer/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.